Live Breaking News & Updates on அமெரிக்கன் நரம்பியல் சங்கம்

Stay updated with breaking news from அமெரிக்கன் நரம்பியல் சங்கம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

How an Unproven Alzheimer's Drug Got Approved - The New York Times


How an Unproven Alzheimer’s Drug Got Approved
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
The F.D.A. conducted an internal inquiry this year after allegations were made that the agency was collaborating too closely with Biogen, maker of the Alzheimer’s drug Aduhelm.Credit.Andrew Kelly/Reuters
Published July 19, 2021Updated July 20, 2021, 9:29 a.m. ET
Two months before the Food and Drug Administration’s deadline to decide whether to approve Biogen’s controversial Alzheimer’s drug, aducanumab, a council of senior agency officials resoundingly agreed that there wasn’t enough evidence it worked. ....

New York , United States , Samantha Budd Haeberlein , Janet Woodcock , Rick Pazdur , Billy Dunn , Vissia Viglietta , Priya Singhal , Williamb Schultz , Maria Carrillo , Al Sandrock , Patrizia Cavazzoni , Michael Felberbaum , Budd Haeberlein , Wayne Pines , New York Times , Program Review Council , Department Of Health , Human Services , Drug Administration , Alzheimer Association , American Neurological Association , Drug Approved , New Drug , Public Citizen , Drug Evaluation ,